Clinical Trials Logo

Clinical Trial Summary

Although there are several tools that can be used to evaluate the severity of ongoing alcohol withdrawal syndrome (AWS), there is no available tool that can predict which patients are at risk for developing AWS at the time admission, before the patient has developed AWS. Unfortunately, there are severe symptoms of alcohol withdrawal (e.g., seizures) which may develop early in the hospitalization, and before the development of other systemic symptoms which may warn medical personnel of the possibility of impeding alcohol withdrawal (e.g., autonomic instability, delirium). The goal of this study is to evaluate the psychometric properties (e.g., predictive validity) of a new tool, the Prediction of Alcohol Withdrawal Severity Scale (PAWSS), on identifying which patients are at risk for developing complicated AWS (i.e., seizures, hallucinosis, delirium tremens) among hospitalized, medically ill patients.


Clinical Trial Description

The investigators plan to study the psychometric properties of a new tool, the "Prediction of Alcohol Withdrawal Severity Scale" (PAWSS) on predicting the risk for the development of complicated AWS (i.e., seizures, delirium tremens) in hospitalized medically ill patients. This tool was developed through an extensive literature review which identified evidence-based predictors for AWS.

The scale consists of three portions relating to 1) an initial screening (threshold items), 2) patient's history of alcohol use and its consequences, and 3) measures of BAL and autonomic function. The investigators predict that a scale score 4 or greater will be associated with a high risk for the development of complicated AWS.

Patients will undergo examination with the PAWSS within 24 hours of hospital admission. Thereafter, all patients will undergo daily examinations with the Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA) and the Alcohol Withdrawal Severity scale (AWS scale) in order to measure the primary outcomes of the study, that is, the development and severity (i.e., moderate to severe) of AWS during the first 72-hours after admission. The study is designed to study the tool's psychometric properties including its validity and inter-rater reliability.

By providing clinicians with a tool (i.e., PAWSS) that allows them to correctly predict who will develop complicated AWS it will enable them to prophylax (i.e., preventively treat) patients at risk and thus decrease patients' morbidity and mortality, shorten length of hospital stay, minimize the significant burden on the nursing and medical staff, and improve overall patient care. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01637415
Study type Observational
Source Stanford University
Contact
Status Completed
Phase N/A
Start date May 2012
Completion date June 2014

See also
  Status Clinical Trial Phase
Completed NCT03033823 - MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA) Phase 3
Completed NCT02146716 - Assessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms. N/A
Completed NCT04973202 - Portrayal of Hospital Alcohol Detoxification in France
Terminated NCT02052440 - Preventing Alcohol Withdrawal Syndrome With Oral Baclofen Phase 3
Completed NCT01652326 - Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome N/A
Recruiting NCT03235531 - Assessment of Valproate on Ethanol Withdrawal Phase 4
Completed NCT00146471 - Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome Phase 3
Completed NCT02090504 - Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome Phase 4
Completed NCT03012815 - Gabapentin for Alcohol Withdrawal Syndrome Phase 4
Completed NCT05438641 - Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants
Completed NCT00249366 - Treatment of Alcohol Withdrawal in Hospital Patients Phase 4
Withdrawn NCT03788889 - Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine Phase 4